Eli Lilly's GLP-1 Trial Data in Focus as Earnings Take Backseat, Says Cramer
CNBC's Jim Cramer suggests that upcoming clinical trial updates for Eli Lilly's GLP-1 drugs, rather than quarterly earnings, are the primary catalyst investors should watch for potential stock movement.